Karriereverlauf von Nicolas Koebel
Ehemalige bekannte Positionen von Nicolas Koebel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Gründer | 01.10.2015 | 01.08.2022 |
| Corporate Officer/Principal | 01.10.2015 | 01.08.2022 | |
| ORCHARD THERAPEUTICS PLC | Gründer | 01.08.2018 | - |
| Corporate Officer/Principal | 01.08.2018 | - |
Ausbildung von Nicolas Koebel
| Institut D'études Politiques De Strasbourg | Graduate Degree |
| Institut de hautes études internationales et du développement | Undergraduate Degree |
Statistik
International
| Vereinigtes Königreich | 3 |
| Frankreich | 2 |
| Schweiz | 2 |
Operativ
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Nicolas Koebel
- Erfahrung
